What is the price of one tube of talquetamab (talquetamab-tgvs) on the market?

Talquetamab is a bispecific antibody drug with innovative immunotherapy properties. Its mechanism is through dual targeting: one end binds to the GPRC5D receptor on the surface of multiple myeloma cells, and the other end binds to the CD3 molecule on the surface of T cells, thereby accurately guiding T cells to the surrounding tumor cells and achieving specific killing of cancer cells by the immune system. This drug can not only enhance the anti-tumor immune response, but also minimize damage to normal tissues. Compared with traditional chemotherapy and monoclonal antibody therapy, it has higher targeting and potential efficacy advantages. The research and development background of Taquitutumab is based on immune cell therapy strategies, aiming to solve the problem of limited efficacy in traditional treatments for patients with relapsed or refractory multiple myeloma.

In terms of clinical application, Taquinutumab is mainly used for patients with relapsed or refractory multiple myeloma, especially those who have poor response to previous drug treatments or whose disease progresses rapidly. The drug is usually administered by subcutaneous injection or intravenous infusion, and professional assessment is required before each administration, including tumor burden, hematological indicators and immune function status. In addition, to reduce infusion-related risks, clinical practice often involves appropriate pretreatment before administration, such as the use of antihistamines or low-dose corticosteroids.

Taquitumumabhas shown potential for tumor control and quality of life improvement in treatment. By specifically targeting GPRC5D, drugs can directly act on myeloma cells, reduce tumor burden, and delay disease progression to a certain extent. At the same time, by mobilizing the immune activity of T cells, it enhances the anti-tumor response in the body and improves the therapeutic response rate of relapsed patients. Clinical studies have shown that the drug may cause cytokine release syndrome, rash, fatigue, or hematological changes, but most side effects can be controlled through monitoring and symptomatic management.

Reference materials:https://www.drugs.com